Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03786003

ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)

This study is one of Eastern Cooperative Thoracic Oncology Projects (ECTOP-1007). The goal of this study is to determine video-assisted thoracoscopic surgery is non-inferior to thoracotomy in terms of disease-free survival for solid clinical stage T1N0M0 NSCLC.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

It is a randomized clinical trial comparing video-assisted thoracoscopic surgery (VATS) with thoracotomy for solid clinical stage T1N0M0 NSCLC. The primary objective of the study is to determine that VATS is non-inferior to thoracotomy in terms of disease-free survival (DFS). Secondary objectives are to compare VATS and thoracotomy for overall survival (OS), perioperative complications, pain levels and quality of life.

Although there are numerous retrospective studies have indicated feasibility and effectiveness of VATS, no data has been reported from those prospective and randomized clinical trials with prognostic indicators as the primary objective. Whether VATS is non-inferior to thoracotomy in terms of survival is still unclear. Therefore, we design this trial by recruiting patients in clinical stage T1N0M0 with solid mass on computed tomography (CT). To determine the clinical stage, CT scans will be performed routinely and PET-CT/EBUS-TBNA/mediastinoscopy will be conducted in patients with suspected positive mediastinum lymph node or distant metastases. Detailed inclusion criteria include clinical stage T1N0M0 and surgical resectable, solid appearance on CT, age 18 to 75 year and signed informed consent. Exclusion criteria includes not NSCLC in pathologic analysis, no lobectomy or sublobar resection, history of other malignant tumors within 5 years, history of thoracic surgery or unsuitable for VATS and previous radiation or chemotherapy.

In our previous data, the 3-year DFS for cT1N0M0 patients with solid mass who were subjected to thoracotomy (lobectomy or sublobar resection) was 77.9%. If the 3-year DFS of VATS arm is not less than 70.9%, the VATS arm will be regarded to be non-inferior to thoracotomy. A sample size of at least 1086 participants is required for performance equal to 80%, α-level equal to 0.025, 1:1 recruitment and considering a dropout rate of 10%. Participants will be randomly assigned to either group using a random table.

Lobectomy or sublobar resection will be conducted by standard procedures at the discretion of the surgeon. Each participating surgeon will be evaluated by the trial committee to ensure proper surgical technique. If the VATS is diverted to thoracotomy intraoperartively, the reason will be recorded, and the cause will still be analyzed in an intention-to-treat analysis. Patients will be follow-up every 6 months to 3 years after surgery.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical stage T1N0M0 and surgical resectable.
  • Solid appearance on computed tomography scan.
  • Age 18 to 75 year.
  • Signed the informed consent form.

Exclusion criteria

  • Not NSCLC in pathological analysis.
  • Not lobectomy or sublobar resection.
  • History of other malignant tumors within 5 years.
  • History of thoracic surgery or unsuitable for VATS.
  • Previous radiation or chemotherapy.

Treatment and study plan

VATS

Procedure

Standard video assisted thoracic surgery, no use of rib-spreader.

thoracotomy

Procedure

Standard thoracotomy

Primary outcomes

  1. Disease-free survival

    Time frame: 3 years after the surgery

    Disease-free survival means the period after surgery when no disease can be detected.

Secondary outcomes

  1. Overall survival

    Time frame: 3 years after the surgery

    Overall survival means the period after surgery when a patient doesn't die directly from lung cancer or an unrelated cause.

  2. Rate of patients with perioperative complication

    Time frame: 1 month after surgery

    The perioperative complication includes wound infection, hemorrhage, infection, pleural effusion, pneumothorax, cardiovascular problem and etc within a month after surgery.

  3. Pain degree and quality of life

    Time frame: 1 years after the surgery

    Numerical rating score (NRS)

Study contacts

Contact information is provided by the study sponsor or research team.

Haiquan Chen, Ph.D

CONTACT

Haoxuan Wu, M.D.

CONTACT

[email protected]

86-13901770461

Sponsors and collaborators

Lead sponsor

Fudan University

Other

Registry information

Official study title

Lobectomy for Clincial Stage T1N0M0 Solid NSCLC by VATS Versus Thoracotomy

Important dates

Study start
2022
Primary completion
2025
Study completion
2028
First posted
Dec 24, 2018
Registry last updated
Jul 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.